Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia.
Motta I, Consonni D, Stroppiano M, Benedetto C, Cassinerio E, Tappino B, Ranalli P, Borin L, Facchini L, Patriarca A, Barcellini W, Lanza F, Filocamo M, Cappellini MD; Splenomegaly Gaucher group. Motta I, et al. Among authors: borin l. Sci Rep. 2021 Jan 28;11(1):2594. doi: 10.1038/s41598-021-82296-z. Sci Rep. 2021. PMID: 33510429 Free PMC article. Clinical Trial.
Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: kinetics of its appearance and potential predictive role in infectious complications.
Belotti A, Duca L, Borin L, Realini S, Renso R, Parma M, Pioltelli P, Pogliani E, Cappellini MD. Belotti A, et al. Among authors: borin l. Leuk Res. 2015 Jan;39(1):88-91. doi: 10.1016/j.leukres.2014.11.003. Epub 2014 Nov 15. Leuk Res. 2015. PMID: 25435028 Clinical Trial.
Skeletal involvement in type 1 Gaucher disease: Not just bone mineral density.
Baldini M, Casirati G, Ulivieri FM, Cassinerio E, Khouri Chalouhi K, Poggiali E, Borin L, Burghignoli V, Cesana BM, Cappellini MD. Baldini M, et al. Among authors: borin l. Blood Cells Mol Dis. 2018 Feb;68:148-152. doi: 10.1016/j.bcmd.2017.06.003. Epub 2017 Jun 16. Blood Cells Mol Dis. 2018. PMID: 28693786
Nilotinib induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia.
Pungolino E, Rossi G, De Canal G, Trojani A, D'adda M, Perego A, Orlandi EM, Lunghi F, Turrini M, Borin L, Iurlo A, Latargia ML, Carraro MC, Spina F, Lodola M, Artale S, Anghilieri M, Spedini P, Cantoni S, Di Camillo B, Morra E, Cairoli R. Pungolino E, et al. Among authors: borin l. Am J Hematol. 2018 Jul;93(7):E162-E164. doi: 10.1002/ajh.25106. Epub 2018 May 17. Am J Hematol. 2018. PMID: 29633310 Free article. No abstract available.
Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study.
Pungolino E, D'adda M, De Canal G, Trojani A, Perego A, Elena C, Lunghi F, Turrini M, Borin L, Iurlo A, Latargia ML, Carraro MC, Spina F, Artale S, Anghilieri M, Molteni A, Caramella M, Baruzzo G, Nichelatti M, Di Camillo B, Cairoli R. Pungolino E, et al. Among authors: borin l. Eur J Haematol. 2021 Oct;107(4):436-448. doi: 10.1111/ejh.13680. Epub 2021 Jul 6. Eur J Haematol. 2021. PMID: 34139044 Free PMC article. Clinical Trial.
Communicating the diagnosis of a hematological neoplastic disease to patients' minor children: a multicenter prospective study.
Manghisi B, Borin L, Monaco MR, Sacco GGA, Antolini L, Mantegazza R, Barichello M, Mazza U, Zappasodi P, Onida F, Arcaini L, Cairoli R, Gambacorti Passerini C. Manghisi B, et al. Among authors: borin l. Oncologist. 2024 May 22:oyae104. doi: 10.1093/oncolo/oyae104. Online ahead of print. Oncologist. 2024. PMID: 38775839 Free article.
The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda".
Molteni A, Riva M, Borin L, Bernardi M, Pelizzari AM, Freyrie A, Della Porta M, Nichelatti M, Ravano E, Quaresmini G, Mariotti J, Caramazza D, Ubezio M, Guarco S, Gigli F, Greco R, Cairoli R, Morra E. Molteni A, et al. Among authors: borin l. Leuk Res. 2016 Mar;42:21-7. doi: 10.1016/j.leukres.2016.01.006. Epub 2016 Jan 18. Leuk Res. 2016. PMID: 26852003
Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment.
Trojani A, Pungolino E, Rossi G, D'Adda M, Lodola M, Camillo BD, Perego A, Turrini M, Orlandi E, Borin L, Iurlo A, Malato S, Spina F, Latargia ML, Lanza F, Artale S, Anghilieri M, Carraro MC, Canal G, Morra E, Cairoli R. Trojani A, et al. Among authors: borin l. Cancer Biomark. 2017 Dec 12;21(1):41-53. doi: 10.3233/CBM-170209. Cancer Biomark. 2017. PMID: 29036785
Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes.
Piciocchi A, Sargentini V, Cotugno F, Bontempi K, Beltrami G, Di Tucci AA, Riva M, Quaresmini G, Vallisa D, Finelli C, Borin L, Fazi P, Vignetti M, Angelucci E. Piciocchi A, et al. Among authors: borin l. Eur J Haematol. 2019 May;102(5):442-443. doi: 10.1111/ejh.13222. Epub 2019 Mar 13. Eur J Haematol. 2019. PMID: 30776156 No abstract available.
Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment.
Trojani A, Pungolino E, Dal Molin A, Lodola M, Rossi G, D'Adda M, Perego A, Elena C, Turrini M, Borin L, Bucelli C, Malato S, Carraro MC, Spina F, Latargia ML, Artale S, Spedini P, Anghilieri M, Di Camillo B, Baruzzo G, De Canal G, Iurlo A, Morra E, Cairoli R. Trojani A, et al. Among authors: borin l. PLoS One. 2019 Jul 18;14(7):e0218444. doi: 10.1371/journal.pone.0218444. eCollection 2019. PLoS One. 2019. PMID: 31318870 Free PMC article. Clinical Trial.
53 results